How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial?

How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial?

CLICK HERE FOR CME CREDIT

How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial? 

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Matthew Roe, MD

Matthew Roe, MD

Professor of Medicine Duke Clinical Research Institute Duke University School of Medicine Durham, NC